
OTLK Stock Forecast & Price Target
OTLK Analyst Ratings
Bulls say
Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody for various ophthalmic indications. The company has received marketing authorization for the product in the European Union and United Kingdom for the treatment of wet age-related macular degeneration. With promising clinical trial results and a strong market potential in Europe, the company has a positive outlook for potential FDA approval in the US and potential growth in commercial sales. Additionally, the company's proprietary formulation of bevacizumab could potentially replace compounded bevacizumab, leading to significant pricing and reimbursement advantages. However, the company needs to address the issues raised by the FDA in their Complete Response Letter and demonstrate a clear path to FDA approval for a more optimistic outlook.
Bears say
Outlook Therapeutics is currently facing various challenges and uncertainties, including potential approval roadblocks in the US, disappointing European unit sales, and the need for additional financing. These challenges could impact the company's potential revenue and profitability, and as a result, it is prudent to take a wait-and-see approach before considering a positive outlook on the stock. Furthermore, the company's recent quarterly results showed a higher-than-expected loss per share and a decrease in cash and cash equivalents, highlighting its financial struggles. Given these factors, it is logical to have a neutral stance on the stock for now.
This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OTLK Analyst Forecast & Price Prediction
Start investing in OTLK
Order type
Buy in
Order amount
Est. shares
0 shares